DSS News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$6.1M

Volume

3.40K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

DSS, Inc. Announces Decision Not to Proceed with Proposed Public OfferingDSS, Inc. announced on September 4, 2026, that it has decided not to proceed with its previously announced public offering of Common Stock due to limited capacity under its existing shelf registration statement. The company continues to explore alternative capital-raising options while remaining focused on shareholder value creation.GlobeNewswire Inc. · Sep 4, 2026

DSS, Inc. Announces Launch of Proposed Public OfferingDSS, Inc. announced the commencement of a public offering of Common Stock on the NYSE American under ticker DSS. The company intends to use net proceeds for general corporate and working capital needs. Aegis Capital Corp. is serving as the sole book-running manager. The offering is subject to market conditions and completion is not assured.GlobeNewswire Inc. · Sep 4, 2026

DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K FilingDSS, Inc. announced that its 2025 annual report (10-K) filed on March 31, 2026, includes a 'going concern' qualification from auditor HTL International LLC. The company clarified this announcement does not represent any change or amendment to its financial statements. DSS operates across product packaging, biotechnology, commercial lending, and securities management.GlobeNewswire Inc. · May 8, 2026

Impact Biomedical (IBO) Stock Jumps Over 86% After Hours — Here's WhyImpact Biomedical (IBO) shares surged 86.28% in after-hours trading to $0.77 following an SEC filing that disclosed amendments to its pending merger with Dr Ashleys Bio Labs Limited. The merger agreement was extended from March 31 to July 1, 2026, with revised share allocations. Dr Ashleys will issue 169.5 million shares (94.20% of total), while parent company DSS will receive 53,000 shares with potential for 75,000 additional shares if funding obligations are met.Benzinga · Mar 5, 2026

DSS, Inc. Announces Launch of Proposed Public OfferingDSS, Inc. (NYSE: DSS) announced the commencement of a public offering of Common Stock to raise capital for general corporate and working capital needs. Aegis Capital Corp. is serving as the sole book-running manager for the offering, which is subject to market conditions and SEC registration requirements.GlobeNewswire Inc. · Feb 4, 2026

DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic MergerDSS, Inc. announced that its subsidiary, Impact BioMedical Inc., has entered into a definitive merger agreement with Dr. Ashleys Limited, a global pharmaceutical company. The transaction will result in a newly formed combined entity traded on the NYSE American under the name 'Dr Ashleys Limited'.Benzinga · Jun 24, 2025

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform.GlobeNewswire Inc. · Jan 30, 2024

DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open MarketChairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in CompanyGlobeNewswire Inc. · Jan 4, 2024

Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. DouYu plans repurchase of up to $20 million of ordinary shares in the form of ADSS during period of up to twelve months commencing on Jan. 1, 2024. DouYu International shares jumped 14.2% to $0.8320 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Nova LifeStyle, Inc. (NASDAQ: NVFY) shares jumped 204% to $4.71. Cingulate Inc. (NASDAQ: CING) climbed 157.4% to $10.27. On Tuesday, Cingulate received FDA guidance for CTx-1301 (dexmethylphenidate), its lead investigational product candidate for attention deficit hyperactivity disorder (ADHD). Bone Biologics Corporation (NASDAQ: BBLG) gained 62.2% to $7.54. SenesTech, Inc. (NASDAQ: SNES) shares climbed 50.7% to $1.30. HC Wainwright & Co. analyst Amit Dayal maintained SenesTech with a Buy, adjusting target to $3.5 from $4. Microbot Medical Inc. (NASDAQ: MBOT) rose 38% to $1.8301 after the company announced the completion of its GLP pivotal pre-clinical study. Sidus Space, Inc. (NASDAQ: SIDU) gained 32% to $5.81. DatChat, Inc. (NASDAQ: DATS) rose 30% to $2.62. DatChat announced the release of its new AI social gaming platform and developer program for game designers and content creators. SEALSQ Corp (NASDAQ: LAES) gained 25% to $1.4424. SEALSQ disclosed that its post-quantum semiconductor technology, based on cutting-edge cryptographic algorithms, is specifically designed to withstand attacks from and secure cryptocurrency transactions against the looming threat of quantum computing. Ocean Biomedical, Inc. (NASDAQ: OCEA) surged 21.4% to $0.7299. DSS, Inc. (NYSE: DSS) jumped 21% to $0.1477. RenovoRx, Inc. (NASDAQ: RNXT) gained 20% to $1.2599. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose 20% to $3.6250. The FDA recently approved the company's Zoryve topical foam, 0.3% for seborrheic dermatitis in individuals nine years and older. Envoy ...Benzinga · Dec 28, 2023

DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance PlanNEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, today announced that it will proceed with a 1-for-20 reverse stock split (the “Reverse Split”) of its issued and outstanding shares of common stock, par value $0.02, following authorization by its Board of Directors and majority shareholders to effect a reverse split by a ratio of not less than 1-for-20 and not more than 1-for-40 (the “Reverse Split Range”), at any time on or before April 20, 2024, with the Board having the discretion as to whether or not the Reverse Split is to be effected, and with the exact ratio to be set at a whole number within the Reverse Split Range as determined by the Chief Executive Officer in his discretion.GlobeNewswire Inc. · Dec 22, 2023

DSSDSS, Inc.

DSS

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any DSS yet.

Related Tickers

Earnings

Mkt Cap

$6.1M

Volume

3.40K

Next Earnings

November 13th